bioAffinity Technologies, Inc. - SIC # 8071 - MEDICAL LABORATORIES

Ticker Exchange SIC # Website Latest Ticker
BIAF Nasdaq 8071 bioaffinitytech.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for bioAffinity Technologies, Inc.

bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements - Sep 9th, 2026 6:00 am
bioAffinity’s AI Lung-Cancer Stock Jumped Nearly 48% After a Reverse Split. What Would Have to Go Right? - Sep 5th, 2026 12:13 am
bioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Sep 3rd, 2026 2:30 pm
bioAffinity Technologies Shares Rise After CyPath Lung Surveillance Update - Sep 3rd, 2026 6:21 am
bioAffinity Technologies Advances CyPath Lung for Post-Treatment Lung Cancer Surveillance - Sep 1st, 2026 9:03 am
bioAffinity Technologies Advances CyPath® Lung for Surveillance of Lung Cancer Survivors - Sep 1st, 2026 6:00 am
bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026 - Aug 20th, 2026 6:00 am
bioAffinity Technologies Signs Nationwide Federal Healthcare Distribution Agreement for CyPath Lung - Aug 18th, 2026 8:43 am
bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung - Aug 18th, 2026 6:00 am
WallachBeth Capital Announces Closing of bioAffinity Technologies $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules - Aug 14th, 2026 9:45 am
bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules - Aug 14th, 2026 9:07 am
WallachBeth Capital Announces bioAffinity Technologies Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules - Aug 13th, 2026 8:00 am
bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules - Aug 13th, 2026 7:07 am
bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung - Aug 7th, 2026 6:00 am
bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung - Jul 27th, 2026 6:08 am
BIAF vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now? - Jul 24th, 2026 7:04 am
bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD - Jul 22nd, 2026 6:08 am
BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell? - Jul 9th, 2026 11:34 am
bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues - Jul 7th, 2026 6:46 am
Q2 Virtual Investor Summit Presentations Now Available On Demand - Jun 30th, 2026 11:20 am